Ultragenyx’s Angelman therapy fails Phase 3 trial in setback for

In a major setback to the search for a treatment for the rare neurodevelopmental disease known as Angelman syndrome, Ultragenyx said a Phase 3 trial of its experimental therapy failed. The company's antisense oligonucleotide therapy ...